This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Outcomes assessed in the review
The following model parameters were identified from published papers.
The probability of the following transitions in a 3-month period: psychosis to recovered on conventional antipsychotics and on clozapine, recovered to relapse on conventional antipsychotics and on clozapine, death by suicide on conventional antipsychotics and on clozapine, no tardive dyskinesia to tardive dyskinesia on conventional antipsychotics, no agranulocytosis to agranulocytosis on clozapine, and agranulocytosis to death on clozapine; and the sensitivity and specificity of pharmacogenetic tests.
Study designs and other criteria for inclusion in the review
Not reported.
Sources searched to identify primary studies
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
The model parameters were identified using data from 10 published papers.
Methods of combining primary studies
Not relevant.
Investigation of differences between primary studies
Results of the review
The following model parameters were identified.
The probability of the following transitions in a 3-month period: psychosis to recovered on conventional antipsychotics, 40%; psychosis to recovered on clozapine, 42.9%;
